Boxed warning
Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children . In case of accidental overdose, call a doctor or poison control center immediately.
PreferaOB plus DHA
- Manufacturer
- Alaven Pharmaceutical LLC | Nexgen Pharma Inc. | Carton Services Inc
- Effective date
- 2011-01-18
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:51:52
Label at a glance#
ProductPreferaOB plus DHA
Active ingredientFOLIC ACID, Heme Iron Polypeptide, IRON DEXTRAN, Potassium Iodide, Zinc Oxide, Selenium, CUPRIC SULFATE, CHOLECALCIFEROL, THIAMINE MONONITRATE, ALPHA-TOCOPHEROL SUCCINATE, D-, RIBOFLAVIN, NIACINAMIDE, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN, BIOTIN, CALCIUM PANTOTHENATE
Label structure12 sections
Indications and uses
PreferaOB + DHA™ is a prescription multivitamin/multimineral ( PreferaOB ® ) and Omega-3 fatty acid ( life'sDHA ™) nutritional supplement indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and non-lactating mothers. PreferaOB + DHA™ is also beneficial in improving the nutritional status of women prior to conception.
Dosage and administration
One tablet and one softgel daily with or without food, or as prescribed by a licensed health care provider with prescribing authority.
Contacts and useful links#
Websitewww.preferaob.com
www.PreferaOB.com
www.PreferaOB.comLabel contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Rx Only
DESCRIPTION
PreferaOB + DHA™ is a prescription prenatal/postnatal multivitamin/multimineral (PreferaOB ®) and Omega-3 fatty acid (life'sDHA™) nutritional supplement. PreferaOB + DHA™ is: a small, oval, film-coated, purple tablet with black core, debossed and bisected with "AP/84" on one side, and plain on the other (PreferaOB ®) and a clear essential fatty acid softgel containing an amber to light/dark orange semi-solid mixture (life'sDHA™).
| Each PreferaOB® tablet contains: | |
| VITAMINS | |
| D3 (as cholecalciferol) | 400 IU |
| E (as d-alpha tocopheryl succinate) | 10 IU |
| B1 (as thiamin mononitrate) | 1.5 mg |
| B2 (as riboflavin) | 1.6 mg |
| B3 (niacin as niacinamide) | 17 mg |
| B6 (as pyridoxine HCl) | 50 mg |
| Folic Acid | 1 mg |
| B12 (as cyanocobalamin) | 12 mcg |
| Biotin | 30 mcg |
| B5 (as d-calcium pantothenate) | 10 mg |
| MINERALS | |
| Iron | |
| as Polysaccharide Iron Complex (a complex of iron, glucose, maltose, and dextrin; Iron Content ~ 46%) yielding | 28 mg |
| as HIP (heme iron polypeptide as Proferrin®** - bovine source, USDA certified) yielding | 6 mg |
| Iodine (as potassium iodide) | 250 mcg |
| Zinc (as zinc oxide) | 4.5 mg |
| Selenium (as sodium selenate) | 65 mcg |
| Copper (as cupric sulfate) | 0.8 mg |
INACTIVE INGREDIENTS:
Microcrystalline cellulose, croscarmellose sodium, crospovidone, magnesium stearate (vegetable source), silicon dioxide, dextran, dicalcium phosphate, protease, modified food starch, sucrose, dl-alpha tocopherol, sodium ascorbate, ethylcellulose, resin, coating (polydextrose, hypermellose, titanium dioxide, D&C red no. 30 aluminum lake, FD&C blue no. 2 aluminum lake, polyethylene glycol, hydroxypropyl cellulose, purified water).
| Each life'sDHA™ Softgel contains: | |
| Total omega-3 long chain fatty acids | 203 mg |
| as Docosahexaenoic Acid (DHA) | 200 mg |
| as α-linolenic acid (ALA) | 0.5 mg |
| as Docosapentaenoic acid (DPA) | 2.5 mg |
DHA is derived from the oils of microalgae, which is grown outside of the ocean, in a controlled environment, eliminating the risk of oceanic contamination. Ingredients include: DHA Algal Oil, High Oleic Sunflower Oil, Ascorbyl Palmitate & Tocopherols (as antioxidants) in a Gelatin Capsule (Gelatin, Glycerin, Water, and Caramel, Carmine, Calcium Carbonate and Turmeric as coloring).
INDICATIONS AND USAGE
PreferaOB + DHA™ is a prescription multivitamin/multimineral (PreferaOB ®) and Omega-3 fatty acid (life'sDHA™) nutritional supplement indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and non-lactating mothers. PreferaOB + DHA™ is also beneficial in improving the nutritional status of women prior to conception.
CONTRAINDICATIONS
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
WARNING
Ingestion of more than 3 grams of omega-3 fatty acids per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR). Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding diathesis.
WARNING
Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
PRECAUTIONS
Folic acid when administered as a single agent in doses above 0.1mg daily may obscure pernicious anemia in that hematological remission can occur while neurological manifestations remain progressive. Pregnant women and nursing mothers should avoid supplemental doses of vitamin E higher than RDA amounts. While prescribing this nutritional supplement for pregnant women, nursing mothers, or for women prior to conception, their medical condition and other drugs, herbs, and/or supplements consumption should be considered.
ADVERSE REACTIONS
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
DOSAGE AND ADMINISTRATION
One tablet and one softgel daily with or without food, or as prescribed by a licensed health care provider with prescribing authority.
HOW SUPPLIED
PreferaOB + DHA™ is supplied in child-resistant blister packs of 30 tablets and 30 softgels (NDC 68220-083-30) and as a Professional Sample (NDC 68220-083-25).
KEEP OUT OF REACH OF CHILDREN.
STORAGE
Store at controlled room temperature 20°-25°C (68°-77°F). Excursions permitted to 15°-30°C (59°-86°F). [See current USP]
To protect from light, dispense in carton provided. Once open, blisters should be stored in carton.
SPL UNCLASSIFIED SECTION
For medical inquiries call toll free 1-888-317-0001
life'sDHA™
HEALTHY BRAIN, EYES, HEART
Manufactured for:
ALAVEN
®
PHARMACEUTICAL LLC
Alaven® Pharmaceutical LLC, Marietta, GA 30062
U.S. Patent No. 7,585,527
*life'sDHA™ is a trademark of Martek Biosciences Corporation, Columbia, MD.
**Proferrin® is a registered trademark of Colorado Biolabs, Inc., Cozad, NE.
PreferaOB® is a registered trademark and PreferaOB + DHA™ is a
trademark of Alaven® Pharmaceutical LLC, Marietta, GA.
6-083-30-06-0710CR
Ref CL6-083-00-01-0710b
PRINCIPAL DISPLAY PANEL - 30 Tablet Carton
Rx Only
NDC 68220-083-30
30 Tablets + 30 Softgels
PreferaOB
+DHA
™
life'sDHA™
HEALTHY BRAIN, EYES, HEART
ONLY prenatal with Natural,
Body-Ready HEME Iron + DHA
15 Essential Vitamins and
Minerals including:
- 50mg of vitamin B6
- 1mg of folic acid
Plus Plant-based life'sDHA™ Omega-3
Pre/Post-natal Nutritional
Supplement + DHA
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68220-083-05 | 2020-02-04 | C162847 | 48780-1 | 9d75b9d0-a339-f424-e053-dadaa90a57ce | Prenatal/Postnatal Multivitamin/ Multimineral PreferaOB ® Tablets & life'sDHA™* Softgels |
| 68220-083-30 | 2020-02-04 | C162847 | 48780-1 | 9d75b9d0-a339-f424-e053-dadaa90a57ce | Prenatal/Postnatal Multivitamin/ Multimineral PreferaOB ® Tablets & life'sDHA™* Softgels |
| 68220-083-05 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-a339-f424-e053-dadaa90a57ce | Prenatal/Postnatal Multivitamin/ Multimineral PreferaOB ® Tablets & life'sDHA™* Softgels |
| 68220-083-30 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-a339-f424-e053-dadaa90a57ce | Prenatal/Postnatal Multivitamin/ Multimineral PreferaOB ® Tablets & life'sDHA™* Softgels |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68220-083-30 | EA - Each | 68220-083 | 56df4ecd-93fa-4dce-8570-c5b5ef777a2b | 1 | 2013-02-13 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ALPHA-TOCOPHEROL SUCCINATE, D- | ACTIVE INGREDIENT | LU4B53JYVE | 1 | |
| BIOTIN | ACTIVE INGREDIENT | 6SO6U10H04 | 1 | |
| CALCIUM PANTOTHENATE | ACTIVE INGREDIENT | 568ET80C3D | 1 | |
| CHOLECALCIFEROL | ACTIVE INGREDIENT | 1C6V77QF41 | 1 | |
| CUPRIC SULFATE | ACTIVE INGREDIENT | LRX7AJ16DT | 1 | |
| CYANOCOBALAMIN | ACTIVE INGREDIENT | P6YC3EG204 | 1 | |
| FOLIC ACID | ACTIVE INGREDIENT | 935E97BOY8 | 1 | |
| Heme Iron Polypeptide | ACTIVE INGREDIENT | 31VDO12CJY | 1 | |
| IRON DEXTRAN | ACTIVE INGREDIENT | 95HR524N2M | 1 | |
| NIACINAMIDE | ACTIVE INGREDIENT | 25X51I8RD4 | 1 | |
| Potassium Iodide | ACTIVE INGREDIENT | 1C4QK22F9J | 1 | |
| PYRIDOXINE HYDROCHLORIDE | ACTIVE INGREDIENT | 68Y4CF58BV | 1 | |
| RIBOFLAVIN | ACTIVE INGREDIENT | TLM2976OFR | 1 | |
| Selenium | ACTIVE INGREDIENT | H6241UJ22B | 1 | |
| THIAMINE MONONITRATE | ACTIVE INGREDIENT | 8K0I04919X | 1 | |
| Zinc Oxide | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| ALPHA-TOCOPHEROL SUCCINATE, D- | ACTIVE MOIETY | LU4B53JYVE | 1 | |
| BIOTIN | ACTIVE MOIETY | 6SO6U10H04 | 1 | |
| CALCIUM PANTOTHENATE | ACTIVE MOIETY | 568ET80C3D | 1 | |
| CHOLECALCIFEROL | ACTIVE MOIETY | 1C6V77QF41 | 1 | |
| COPPER | ACTIVE MOIETY | 789U1901C5 | 1 | |
| CYANOCOBALAMIN | ACTIVE MOIETY | P6YC3EG204 | 1 | |
| FOLIC ACID | ACTIVE MOIETY | 935E97BOY8 | 1 | |
| Heme Iron Polypeptide | ACTIVE MOIETY | 31VDO12CJY | 1 | |
| Iodine | ACTIVE MOIETY | 9679TC07X4 | 1 | |
| IRON DEXTRAN | ACTIVE MOIETY | 95HR524N2M | 1 | |
| NIACINAMIDE | ACTIVE MOIETY | 25X51I8RD4 | 1 | |
| PYRIDOXINE | ACTIVE MOIETY | KV2JZ1BI6Z | 1 | |
| RIBOFLAVIN | ACTIVE MOIETY | TLM2976OFR | 1 | |
| Selenium | ACTIVE MOIETY | H6241UJ22B | 1 | |
| THIAMINE | ACTIVE MOIETY | X66NSO3N35 | 1 | |
| Zinc | ACTIVE MOIETY | J41CSQ7QDS | 1 | |
| .ALPHA.-TOCOPHEROL ACETATE, DL- | INACTIVE INGREDIENT | WR1WPI7EW8 | 1 | |
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | INACTIVE INGREDIENT | L11K75P92J | 1 | |
| ASPERGILLUS FLAVUS VAR. ORYZAE PROTEASE | INACTIVE INGREDIENT | Z3GVO2327F | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 1 | |
| D&C RED NO. 30 | INACTIVE INGREDIENT | 2S42T2808B | 1 | |
| DEXTRAN 1 | INACTIVE INGREDIENT | I8LHQ0D645 | 1 | |
| ETHYLCELLULOSES | INACTIVE INGREDIENT | 7Z8S9VYZ4B | 1 | |
| FD&C BLUE NO. 2 | INACTIVE INGREDIENT | L06K8R7DQK | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) | INACTIVE INGREDIENT | 461P5CJN6T | 1 | |
| POLYETHYLENE GLYCOL | INACTIVE INGREDIENT | 3WJQ0SDW1A | 1 | |
| POLYVINYL ALCOHOL | INACTIVE INGREDIENT | 532B59J990 | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| SODIUM ASCORBATE | INACTIVE INGREDIENT | S033EH8359 | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 |
Products#
Every source-derived product name is available through these pages.
- PreferaOB plus DHA
- FOLIC ACID, Heme Iron Polypeptide, IRON DEXTRAN, Potassium Iodide, Zinc Oxide, Selenium, CUPRIC SULFATE, CHOLECALCIFEROL, THIAMINE MONONITRATE, ALPHA-TOCOPHEROL SUCCINATE, D-, RIBOFLAVIN, NIACINAMIDE, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN, BIOTIN, and CALCIUM PANTOTHENATE
- FOLIC ACID
- Heme Iron Polypeptide
- IRON DEXTRAN
- Potassium Iodide
- Iodine
- Zinc Oxide
- Zinc
- Selenium
- CUPRIC SULFATE
- COPPER
- CHOLECALCIFEROL
- THIAMINE MONONITRATE
- THIAMINE
- ALPHA-TOCOPHEROL SUCCINATE, D-
- RIBOFLAVIN
- NIACINAMIDE
- PYRIDOXINE HYDROCHLORIDE
- PYRIDOXINE
- CYANOCOBALAMIN
- BIOTIN
- CALCIUM PANTOTHENATE
- CELLULOSE, MICROCRYSTALLINE
- CROSCARMELLOSE SODIUM
- MAGNESIUM STEARATE
- SILICON DIOXIDE
- DEXTRAN 1
- ANHYDROUS DIBASIC CALCIUM PHOSPHATE
- SUCROSE
- ASPERGILLUS FLAVUS VAR. ORYZAE PROTEASE
- MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE)
- .ALPHA.-TOCOPHEROL ACETATE, DL-
- SODIUM ASCORBATE
- ETHYLCELLULOSES
- POLYVINYL ALCOHOL
- POLYETHYLENE GLYCOL
- TALC
- TITANIUM DIOXIDE
- D&C RED NO. 30
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68220-083 | 68220-083-05, 68220-083-30 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| TALC | TALC | 7SEV7J4R1U | TABLET, FOR SUSPENSION / ORAL | 24 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | PASTE, DENTIFRICE / DENTAL | 0.4 %w/w | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET, EXTENDED RELEASE / ORAL | 360 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| ETHYLCELLULOSES | ETHYLCELLULOSE | 7Z8S9VYZ4B | TABLET, FILM COATED / ORAL | 83 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, EXTENDED RELEASE / ORAL | 300 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| POLYVINYL ALCOHOL | POLYVINYL ALCOHOL | 532B59J990 | CREAM / VAGINAL | 0.5 %w/w | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / BUCCAL | 18 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 357 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| SODIUM ASCORBATE | SODIUM ASCORBATE | S033EH8359 | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | 0.5 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| POLYVINYL ALCOHOL | POLYVINYL ALCOHOL | 532B59J990 | SOLUTION/ DROPS / OPHTHALMIC | 1.4 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| POLYVINYL ALCOHOL | POLYVINYL ALCOHOL | 532B59J990 | SOLUTION / TOPICAL | 1.4 %w/v | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, CHEWABLE / ORAL | 216 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE, DELAYED RELEASE / ORAL | 789.6 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| ETHYLCELLULOSES | ETHYLCELLULOSE | 7Z8S9VYZ4B | TABLET, EXTENDED RELEASE / ORAL | 1120 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | INJECTION / INTRAMUSCULAR | 1 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY, EXTENDED RELEASE / INTRAUTERINE | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FOR SUSPENSION / ORAL | 20100 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, DELAYED RELEASE / ORAL | 72 mg | ||
| ETHYLCELLULOSES | ETHYLCELLULOSE | 7Z8S9VYZ4B | CAPSULE / ORAL | 12.32 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, LIQUID FILLED / ORAL | 12 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SUSPENSION / ORAL | 4441 mg | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET / SUBLINGUAL | 28 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, DELAYED RELEASE / ORAL | 40 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| SODIUM ASCORBATE | SODIUM ASCORBATE | S033EH8359 | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.5 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE, FOR SUSPENSION / ORAL | 278 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| TALC | TALC | 7SEV7J4R1U | POWDER / TOPICAL | 9235 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED / ORAL | 17 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | CAPSULE / ORAL | 401 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SOLUTION / ORAL | 690 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, DELAYED RELEASE / ORAL | 366 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 127 mg | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET, FOR SUSPENSION / ORAL | 406 mg | ||
| TALC | TALC | 7SEV7J4R1U | OINTMENT / TOPICAL | 74.6 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | PASTILLE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 083a5779-4727-430f-ae00-674122bbdf51 | c755a5b6-f304-404a-90d9-09ecee83024c | 2011-01-18 | Boxed warning, Warnings, Adverse reactions | 083a5779-4727-430f-ae00-674122bbdf51 c755a5b6-f304-404a-90d9-09ecee83024c |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.